Clinical Trials Logo

Pneumonia, Pneumococcal clinical trials

View clinical trials related to Pneumonia, Pneumococcal.

Filter by:

NCT ID: NCT03315403 Completed - Clinical trials for Community-acquired Pneumonia

Quantitative Polymerase Chain Reaction for Improved Detection of Pneumococci in CAP "CAPTAIN"

CAPTAIN
Start date: April 5, 2018
Phase:
Study type: Observational

The purpose of this study is to evaluate the added diagnostic value of a quantitative polymerase chain reaction targeting the lytA gene in detecting pneumococci in patients with community-acquired pneumonia.

NCT ID: NCT03303976 Completed - Clinical trials for Pneumonia, Bacterial

Phase I to Test a New Pneumococcal Vaccine

Start date: September 7, 2017
Phase: Phase 1
Study type: Interventional

To obtain first-in-human data on a new candidate vaccine against Streptococcus pneumoniae in healthy adult and elderly volunteers. The study aims to assess the safety and immunogenicity of a bioconjugate investigational vaccine compared to the control group (Pneumovax23).

NCT ID: NCT03197376 Completed - Clinical trials for Pneumonia, Pneumococcal

Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants

Start date: June 21, 2017
Phase: Phase 3
Study type: Interventional

This study will examine the consistency of 3 batches of the Pneumosil vaccine by looking at the immune response in infants. In addition, the study will compare the immunogenicity of the Pneumosil vaccine to another WHO-prequalified vaccine, Synflorix.

NCT ID: NCT02961231 Completed - Clinical trials for Pneumonia, Pneumococcal

Evaluation of PCV Schedules in a Naive Population in Vietnam

Start date: October 1, 2016
Phase: Phase 4
Study type: Interventional

The cost of pneumococcal conjugate vaccine use can be greatly reduced by making use of existing herd immunity to protect children against vaccine type pneumococci. The investigators will reduce the circulation of vaccine type pneumococci to low levels by PCV catch-up campaign; vaccinating all children less than 3 years of age with PCV, after which the investigators will evaluate the ability of a simplified two doses regimen and an alternative one dose regimen to prevent the reintroduction of vaccine type pneumococci compared to the WHO recommended 2 doses schedule.

NCT ID: NCT02592486 Completed - Influenza Clinical Trials

The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

Start date: November 2015
Phase: Phase 4
Study type: Interventional

The immunogenicity of simultaneous administration of quadrivalent influenza vaccine and pneumococcal vaccine was unknown. The purpose of present study is to compare the immunogenicity of simultaneous administration of influenza vaccine and pneumococcal vaccine with that of separate administration.

NCT ID: NCT02538211 Completed - Tetanus Clinical Trials

The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses

Rota-biome
Start date: September 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate if the intestinal microbiota influences rotavirus vaccine immune responses in healthy adult volunteers.

NCT ID: NCT02133469 Completed - Clinical trials for Streptococcal Pneumonia

PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae

Start date: June 2012
Phase: N/A
Study type: Interventional

A parallel-group, randomized, open-label study will be performed in subjects receiving PCV7 and subjects receiving controlled vaccine Hib vaccine, to claim the efficacy of PCV7 in the prevention of NP carriage of vaccine-serotype S. pneumoniae (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F combined) in 2 to 5 years old healthy Chinese children.

NCT ID: NCT02116998 Completed - Clinical trials for Pneumococcal Infections

Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae

Start date: September 2014
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive GEN-004 with adjuvant or placebo. Each subject will receive up to 3 doses at 4 week intervals. Following the third dose, subjects will be inoculated intranasally with S. pneumoniae serotype 6B. Nasal washes to identify S. pneumoniae colonization will be obtained pre-inoculation, and then 2, 7 and 14 days after inoculation. Subjects will also be monitored for safety and tolerability throughout the dosing period, and then for 12 months after their last dose. The purpose of this study is to evaluate the effectiveness of GEN-004 in reducing colonization rates and magnitude of colonization following the S. pneumoniae challenge.

NCT ID: NCT02097472 Completed - Clinical trials for Pneumonia, Pneumococcal

Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers

Start date: April 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of PATH-wSP, administered intramuscularly to healthy Kenyan adults and toddlers who have been primed with a pneumococcal conjugate vaccine (PCV). Additionally, the study will explore whether a measurable immune response is elicited when PATH-wSP is administered to healthy Kenyan adults and toddlers who have been primed with PCV.

NCT ID: NCT01810861 Completed - Clinical trials for Pneumococcal Diseases

Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey

Start date: January 4, 2013
Phase:
Study type: Observational

The aim of this study is to specify the serotype distribution of Streptococcus pneumoniae that causes invasive diseases at children and adults in Turkey.